ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 182

Comprehensive Analysis of Protein Expression in Peripheral Blood Mononuclear Cells From Patients with Behcet’s Disease

Takuya Yoshioka1, Manae Kurokawa2, Yukiko Takakuwa1, Hiromasa Nakano1, Seido Ooka3, Nobuko Iizuka2, Toshiyuki Sato2, Mitsumi Arito2, Kouhei Nagai4, Kazuki Okamoto2, Naoya Suematsu2, Noboru Suzuki5, Shoichi Ozaki6 and Tomohiro Kato2, 1Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 2Dept of Biochemistry, St. Marianna Univ School Med, Kawasaki, Japan, 3St. Marianna University School of Medicine, Kawasaki, Japan, 4Kinki Univ., Kinokawa, Japan, 5Department of Immunology and Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 6Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome and proteomics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases: Periodic Fever Syndromes

Session Type: Abstract Submissions (ACR)

Background/Purpose: To elucidate the pathophysiology of Behcet’s disease (BD) and to establish biomarkers for the disease, we comprehensively analyzed protein expression of peripheral blood mononuclear cells (PBMCs).

Methods: PBMCs were obtained from 16 patients with BD, 16 patients with rheumatoid arthritis (RA), and 16 healthy control (HC) subjects. Proteins, extracted from the PBMCs, were separated by 2-dimensional differential gel electrophoresis. Proteins were identified by mass spectrometry. 

Results: As a result, a total of 563 protein spots were detected. Compared to HC, 14 spots showed significantly higher intensity with more than 1.2 folds, and 9 spots showed significantly lower intensity with less than 1/1.2 folds in BD. The spots with higher intensity included proteins involved in T cell activation, metabolism of pre-mRNAs, and protein trafficking. The spots with lower intensity included cytoskeltal proteins. Similarly, compared to RA, 98 spots showed significantly higher intensity with more than 1.2 folds, and 17 spots showed significantly lower intensity with less than 1/1.2 folds in BD. The spots with higher intensity in BD than in RA included proteins associated with bacteriolysis, oxidation/reduction, activation of transcription, regulation of kinases, and modulation of glycosylation. We completely discriminated the BD patients from the HC subjects and from the RA patients by multivariate analyses of 23 and 35 protein spots, respectively. The analyses using only 1-3 protein spots provided areas under the receiver operating characteristic curves of 0.797-0.898 in the discrimination of the BD patients from the HC subjects, from the RA patients, and from the both HC subjects and RA patients.

Conclusion: Taken together, the protein spots which contributed to the discrimination could be biomarker candidates for BD. In addition PBMC-derived proteins, expression of which was significantly altered in BD, may be involved in the pathophysiology of BD.


Disclosure:

T. Yoshioka,
None;

M. Kurokawa,
None;

Y. Takakuwa,
None;

H. Nakano,
None;

S. Ooka,
None;

N. Iizuka,
None;

T. Sato,
None;

M. Arito,
None;

K. Nagai,
None;

K. Okamoto,
None;

N. Suematsu,
None;

N. Suzuki,
None;

S. Ozaki,
None;

T. Kato,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comprehensive-analysis-of-protein-expression-in-peripheral-blood-mononuclear-cells-from-patients-with-behcets-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology